Premier Fluid Data Presented at US Conference

RNS Number : 1588W

Deltex Medical Group PLC

05 November 2014

 



Deltex Medical Group plc

("Deltex Medical" or the "Company")

Premier fluid data presented at pre-eminent US surgeons' conference

Intra-operative fluid management impacts patient outcome and costs of care

5 November 2014 - Deltex Medical Group plc, the global leader in oesophageal Doppler monitoring ("ODM"), announces the presentation of new data from its research collaboration with Premier Inc.

The presentation, "Increased Risk of Postoperative Ileus with Excess Fluid on the Day of Colon Surgery; Results from 524 Hospitals in the US", was given by Dr. Julie Thacker, assistant professor of surgery at Duke University, at this week's American College of Surgeons Clinical Congress.

The study focused on the specific post-operative complication of ileus, paralysis of the gut, in over 80,000 patients undergoing colorectal surgery. The study found that the 25% of patients who received the lowest amounts of fluid on day of surgery (1.7l or less) had a 12% greater risk of post-operative ileus.  The 25% of patients who received the highest amounts of fluids on day of surgery (5.0l or higher) had a 10% greater risk of post-operative ileus.

Overall, patients suffering an ileus comprised 18% of the population. On average they stayed in hospital for 10 rather than 5.5 days, incurred 50% higher costs ($20,734 v $13,865) and were more likely to be readmitted to hospital (13.7% v 9.4% at 30 days).

The Company's ODM systems have been clinically proven to reduce post-operative complications including ileus.

Dr Thacker commented:

"While a small number of recent studies have appeared to suggest less of a need for day of surgery fluid monitoring techniques for healthier patients, our review showed that fluid variability crossed all patient groups, sick and healthy, as evaluated by comorbidities and diagnosis group.  Implementing 'enhanced recovery' principles, including evidence-based techniques for fluid optimisation, may decrease the variability around an optimal fluid infusion and improve outcomes."

Ewan Phillips, Chief Executive of Deltex Medical, commented:

"This big dataset shows the scale of variation in fluid management across the USA and reinforces the fact that both too little and too much fluid lead to worse outcomes for patients. ODM enables clinicians to administer intra-vascular fluids very precisely during surgery: optimising fluids optimises patients' recoveries after surgery.

"Growing awareness in the USA of the importance of fluid optimisation, supported by the efforts of a number of professional societies and stakeholder groups, is fueling market interest in ODM. We continue to receive enquiries from leading US hospitals. In the past month we have added further high quality hospitals looking to evaluate ODM to our sales pipeline, have completed three major clinical evaluations and are working towards implementation agreements in each of these." 

For further information, please contact:

Deltex Medical Group plc	01243 774 837 [e-mail]
Nigel Keen, Chairman
Ewan Phillips, Chief Executive
Paul Mitchell, Finance Director
Nominated Adviser & Broker
Arden Partners plc	020 7614 5900
Chris Hardie
Joint Broker
Zeus Capital Limited	020 7533 7727
Dominic Wilson John Goold
Financial Public Relations
Newgate Threadneedle	020 7653 9850
Tim Thompson
Heather Armstrong

Notes for Editors

Deltex Medical manufactures and markets CardioQ-ODMÔ Oesophageal Doppler Monitoring ('ODM') systems. ODM is the only therapy to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

The CardioQ-ODM has two distinct established clinical applications: firstly, to guide fluid management during surgery and secondly, to monitor cardiac output in critical care settings.

Surgical market

In March 2011 the National Institute for Health & Clinical Excellence ('NICE') recommended that CardioQ-ODM be considered for use in patients undergoing major and high risk surgery and in high risk patients undergoing intermediate risk surgery. NICE estimated the applicable number of such patients in the NHS in England alone to be over 800,000 each year. CardioQ-ODM has been shown to be effective in both elective and emergency surgery and with both general and regional anaesthetics. This recommendation was specific to CardioQ-ODM and was based on the robust evidence base that supports its use.

Subsequent to the NICE guidance, the NHS in England announced its selection of ODM as a high impact innovation to be rolled out across the system fully, at pace and scale.

The NICE evaluation and recommendation confirms that the potential global market for CardioQ-ODM in surgery includes tens of millions of patients, even if confined to developed health economies: the most conservative estimate of the potential value of the market opportunity Deltex Medical has created is in excess of £1 billion per annum. The Company's core focus is on building market leading positions in this surgical market, both geographically and by type of surgery.

Critical care market

In critical care settings, well-equipped hospitals will often have more than one cardiac output monitoring technology available. In this environment, ODM's strengths are that it is quick to set up, easy to use, safe, low cost and the ideal technology for a patient in crisis requiring rapid or frequent intervention. The potential market for cardiac output monitoring in critical care is a fraction of the size of that for intra-operative fluid management.

Through the 2012 launch of the CardioQ-ODM+, Deltex Medical has added the Pulse Pressure Waveform Analysis ('PPWA') approach to monitoring cardiac output to ODM functionality. Doing this has improved Deltex Medical's offer for monitoring applications as well as providing doctors and nurses with a choice of clinical strategies appropriate to individual patients in different clinical settings.

Company goal

Our goal is to make oesophageal Doppler monitoring (ODM) a standard of care for patients in both these markets. We believe that, in most modern health systems, it is essential to have a robust evidence base of both clinical benefit and cost effectiveness in order to achieve system-wide adoption of a new medical technology. Deltex Medical is one of the very first medical technology companies to have completed the investment necessary to build such an evidence base: as a result, use of ODM during surgery has the proven potential to deliver both clinical and economic benefits that are material at each of patient, hospital and system level.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide and there are already over 3,000 CardioQ-ODM systems in use in hospitals worldwide. Distribution arrangements are in place in over 30 countries.

 

END

 

 

NRAFSIFALFLSEDF